Veraprapas Kittipibul

Oct 22, 2024 | onlinelibrary.wiley.com | Veraprapas Kittipibul |Robert J. Mentz |Rebecca Young |Javed Butler

Introduction The vericiguat global study in subjects with heart failure with reduced ejection fraction (VICTORIA) trial demonstrated a 10% relative and 4.2 events/100 patient-years absolute risk reduction in a composite of heart failure (HF) hospitalization (HFH) or cardiovascular death relative to placebo in patients with high-risk HF.1 Differences in patient risk profiles add complexity to comparing the relative efficacy of vericiguat with other approved contemporary HF therapies.2 Thus, we...

May 15, 2024 | onlinelibrary.wiley.com | Veraprapas Kittipibul |Robert J. Mentz |Robert M. Clare |Daniel Wojdyla

Supporting Information Filename Description ejhf3293-sup-0001-Supinfo.docxWord 2007 document , 215.2 KB Appendix S1. Supporting information. References 1, , , , , , et al.; TRANSFORM-HF Investigators. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: The TRANSFORM-HF randomized clinical trial. JAMA 2023; 329: 214–223. https://doi.org/10.1001/jama.2022.23924 2, , , , , , et al.

Jun 1, 2023 | pubmed.ncbi.nlm.nih.gov | Mentz RJ |Robert J. Mentz |Veraprapas Kittipibul |Anita Deswal

Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software